Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors

Ampaiwan Chuansumrit,1 Pantep Angchaisuksiri2 Nongnuch Sirachainan1

1Departments of Pediatrics and Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Abstract: Hemophilia patients with inhibitors faced the constraint of inadequate treatment for several years before the era of recombinant factor VIIa (rFVII). Initially, rFVIIa was used in the compassionate-use programs. After a worldwide license was issued, more than 1.5 million doses were administered. Bleeding of joints and muscles was controlled effectively by means of an early home treatment program, with either a standard dose of 90 µg/kg every 2 to 3 hours for a few doses or a single dose of 270 µg/kg. For more serious bleeding episodes or minor surgery, an initial dose of 90 µg/kg was given every 2 hours for 24 to 48 hours followed by increased intervals of 3 to 6 hours according to the severity of bleeding and efficacy of bleeding control. In cases of major surgery such as orthopedic procedures, the same regimen can be applied except for a higher initial dose of 120 to 180 µg/kg. However, increasing the dose should be considered if there are unexpected bleeding complications since the half-life and clearance of rFVIIa differ between individuals. In addition, prophylaxis is administered to a small number of patients. Finally, the reported thromboembolic events found in hemophilia patients with inhibitors receiving rFVIIa are extremely low, much less than 1%.

Keywords: bleeding disorder, hemophilia, inhibitor, NovoSeven, recombinant factor VIIa

Introduction

Among patients with hemophilia, 85% to 90% have hemophilia A and 10% to 15% have hemophilia B. The risk of developing inhibitors differs; 25% to 30% of hemophilia A patients develop inhibitors to factor VIII clotting activity,1,2 while only 1% to 3% of hemophilia B patients develop inhibitors to factor IX clotting activity.3 There are two types of inhibitors: low responding and high responding. Low-responding inhibitors occur in approximately 20% to 50% of patients with hemophilia. These patient usually have inhibitor titers below 5 Bethesda units (BU) and, when re-exposed to factor concentrates, do not mount an anamnestic response. Low-responding inhibitors may be transient and disappear spontaneously. They can be treated with a higher dose of factor concentrates. However, some of these may convert to high responding over time. Therefore, careful monitoring should be done periodically. In contrast, inhibitor levels in high responders will rise markedly after being exposed to factor concentrates. Most patients with high-responding inhibitors have titers greater than 10 BU, although if they have not been re-exposed to factor concentrates for some time, baseline titers may be lower. The treatment in these patients is more problematic. Hemophilia patients with inhibitors risk increased morbidity and mortality compared with noninhibitor patients. If inadequately treated, the frequent joint bleeds will lead to synovial inflammation and hypertrophy, and predisposition to recurrent bleeding with progressive damage to the
cartilage and subchondral bone. These patients will suffer from chronic pain requiring frequent hospital visits. They will need devices for facilitating mobility such as wheelchairs and crutches. Also, they will be absent from work and school which results in poor health-related quality of life.

The aim of management of hemophilia patients with inhibitors is to control the bleeding episodes and to eradicate the inhibitors by immune tolerance therapy. However, immune tolerance therapy is not always successful. As a result, various elective surgeries were often delayed or canceled due to inadequate hemostatic achievement. In 1983, Hedner and Kisiel reported the successful use of human plasma derived factor VIIa in the treatment of two hemophilia patients with high-titer inhibitors. Subsequently, the recombinant factor VIIa (rFVIIa; NovoSeven®; Novo Nordisk) was derived from cultured hamster kidney cells using recombinant DNA technology. The development of rFVIIa has opened a new era for hemophilia patients with inhibitors. It has low risk of transfusion-transmitted disease compared to plasma-derived hemostatic agent. Moreover, rFVIIa has not exhibited immunogenicity in hemophilia A and B patients. It has shown effective hemostasis during joint, muscle and soft tissues bleeding as well as minor and major surgeries. There are two mechanisms of action of high-dose FVIIa: 1) tissue factor independent thrombin generation on the activated platelets, resulting in the formation of tight hemostatic fibrin plugs resistant to premature lysis, and 2) FVIIa overcoming competition with zymogen FVII for binding to tissue factor to form factor VIIa-tissue factor complex with subsequent activation of other coagulation factors to generate thrombin. The rFVIIa was used on the compassionate-use programs during 1988 to 1999 and subsequently licensed for the treatment of hemophilia patients with inhibitors in Europe in 1996, Asia in 1997 to 1998 and North America in 1999.

This paper reviews experience with rFVIIa in the treatment of hemophilia patients with inhibitors from the compassionate- and emergency-use programs and from independent published reports from 1988 to 2009.

Materials and methods
For the independent relevant publications assessed in this paper, a literature search (PubMed) from January 1988 through November 2009 was used to identify independent reports of hemophilia patients with inhibitors treated with rFVIIa. The search terms including “activated factor VII”, “rFVIIa”, “recombinant activated FVII”, “NovoSeven” and “rhFVIIa” were used with each of the following: “hemophilia with inhibitors”, “hemophilia and inhibitors to FVIII or FIX”, “congenital hemophilia and inhibitors”. Only English language literature was considered and publications included only those in which patients had inhibitors to factor VIII or factor IX and were treated with rFVIIa.

Compassionate-use programs
Recombinant factor VIIa was available on an emergency- and compassionate-use basis from 1988 to 1999 for the open-label treatment of hemophilia patients with inhibitors to factor VIII or factor IX for life-threatening hemorrhage and hemostasis maintenance during surgery when alternative therapies were unavailable or had already failed to stop bleeding or when complications were foreseen. The treatment was provided on a named-patient basis with a series of case reports. In most studies, the efficacy of rFVIIa in producing hemostasis was evaluated using a global assessment by the physician, the patient, or the patient’s caregiver. The precise definitions used varied between trials but generally, categories such as excellent, effective, partially effective, or ineffective were included. The assessment took into account relief of pain/tenderness, improved joint mobility, size of the bleed, and/or cessation of bleeding. The overall effective response to rFVIIa at the dose ranging from 60 to 120 µg/kg after 8 and 24 hours in the first 55 consecutive bleeds was 91% and 90%, respectively. Recombinant factor VIIa has been given since 1988 to hemophilia patients with inhibitors suffering from life- and limb-threatening bleeds in the central nervous system, intraperitoneum and retroperitoneum, as well as muscle and joint bleedings. The higher dose (around 90 µg/kg) given every 2 to 3 hours was more effective than lower dosages in more serious bleeding situations.

Data on the use of rFVIIa in the treatment of serious nonsurgical bleeding from the noncomparative compassionate- and emergency-use programs have shown that the response was rated as excellent or effective in 62% to 86% of bleeding episodes following treatment with rFVIIa.

Independent published reports
Efficacy of nonsurgical bleeding control
Trials of rFVIIa in hemophilia patients with inhibitors include dose-finding studies and home treatment studies. An initial, randomized, double-blind, dose-finding multicenter study included 179 joint, muscle, and mucocutaneous bleeding episodes in 78 patients treated with two dosages of rFVIIa (35 and 70 µg/kg intravenously every 2 to 3 hours). It demonstrated that the two dosages were similarly effective.
However, a substantial delay before start of treatment (about 7.5 hours longer in the 70 µg/kg group) may have contributed to the lack of difference in efficacy between the two groups. Among hemarthroses, the global response to treatment was excellent or effective in 71% of each dosage group and the mean number of doses per episode of bleeding was 3.1. Data from the compassionate-use programs suggested that a higher dose (around 90 µg/kg) given every 2 to 3 hours was more effective than lower dosages in more serious bleeding situations.

The effect of early treatment as well as regular treatment several times per week in preventing the development of long-term arthropathy is well documented. Early treatment with rFVIIa is more likely to be associated with a successful outcome than late treatment. To facilitate an early initiation of treatment, rFVIIa was studied in a home treatment setting. Recombinant factor VIIa was administered at a dosage of 90 to 100 µg/kg every 2 to 4 hours and treatment had to be initiated within 8 or 12 hours of the onset of bleeding. After about two doses, the hemostatic response was rated as excellent or effective in 79% to 93% of bleeding episodes. After initial resolution, bleeding recurred within 24 to 48 hours in 4% to 5% of episodes.

In one of the noncomparative home treatment studies, the risk of an ineffective or partially effective response was significantly lower if treatment was started within 6 hours of the onset of bleeding than if it was started later (odds ratio 0.24; 95% CI 0.09, 0.63). Combined analyses of data from a dose-finding study, home treatment study, and compassionate use study confirmed the benefits of early treatment for patients with acute hemorrhasis or intramuscular hemorrhage. Fewer doses were needed and higher response rates were achieved when treatment was initiated early. Therefore, in a home treatment setting, rFVIIa was effective in controlling mild to moderate bleeding episodes in hemophilia patients with inhibitors.

Recently, it was shown that the use of higher doses for the treatment of acute bleeding episodes, to achieve full hemostatic effect after one single dose of rFVIIa, is a convenient, safe, and effective, alternative to the repeated dose regimen for hemophilia patients with inhibitors. The effectiveness of treatment with a single dose of rFVIIa 270 µg/kg is similar to that of a standard regimen (90 µg/kg every 3 hours for 3 doses) in hemophilia patients with inhibitors experiencing hemarthroses. The outcomes were similar for the single 270 µg/kg dose and the standard regimen in terms of the treatment response rate, as assessed by patients after 9 hours (25 to 65% versus 31 to 70%, respectively), and the proportion of patients not requiring additional hemostatic medication to control a bleeding episode (91% and 92% versus 86% and 91%). In the open-label study, in which patients were not required to use all three doses of the standard regimen unless necessary, the median number of injections used for this regimen was three and so the median quantity of rFVIIa administered was the same as for the single-dose regimen (270 µg/kg per bleeding episode).

The use of high doses of rFVIIa is also supported by an analysis of data from a registry of hemophilia patients with inhibitors, which found that bolus doses >200 µg/kg were associated with a significantly higher bleed-cessation rate than seen with lower doses (97% of 119 bleeds versus 84% of 436 bleeds; P < 0.01). Successful use of bolus doses as high as 300 µg/kg has been reported.

A single dose of 270 µg/kg rFVIIa is of particular benefit for patients with poor venous access, frequent target-joint hemorrhage, and needle phobia. The single-dose treatment regimen may improve patient compliance, enhance the ease of home treatment, and facilitate earlier control of hemorrhagic events.

Two randomized, open-label, crossover studies comparing rFVIIa with activated prothrombin complex concentrates (aPCC) in the home treatment of hemophilia patients with inhibitors have been reported. Prior to these two studies, a number of studies, most of them single-arm studies and none of them directly comparing rFVIIa and aPCC, have investigated the efficacy of these two agents.

The main finding of the FENOC (FEIBA NovoSeven Comparative) study was that rFVIIa (2 doses of 90–120 µg/kg) and aPCC (1 dose of 75–100 IU/kg) appear to exhibit a similar effect on joint bleeds. The primary endpoint was the proportion of patients reporting effective or partially effective hemostasis at 6 hours after treatment initiation. Six hours after infusion, the rate of effective plus partially effective responses was 78.7% for rFVIIa versus 80.9% for aPCC (90% CI −11.4%–15.7%; P = 0.059). The efficacy of the two treatments was rated differently by a substantial proportion of patients at all time points up to 48 hours. The percentage of discordant pairs (one treatment effective and the other not effective) ranged from 9.8% to 43.8% at different time points, but was highest during the first 12 hours after treatment. Although the objective of this study was to demonstrate equivalence between both products, the statistical criterion to declare both products to be equivalent was not met.

In the second trial, two different regimens of rFVIIa (a single dose of 270 µg/kg and a regimen of 3 doses of
90 µg/kg at 0, 3 and 6 hours; administered in double-blind fashion) were compared with a single dose of aPCC 75 IU/kg (administered unblinded). No statistically significant difference was found between treatment groups with both the binary global response algorithm \( (P = 0.17) \) and the trichotomous global response \( (P = 0.09) \). However, a trend towards increased response was observed in the rFVIIa groups compared with the aPCC group using both global responses. The proportion of patients needing additional “rescue” hemostatic therapy within the first 9 hours was also significantly lower with the single 270 µg/kg dose of rFVIIa treatment than with aPCC (8.3% versus 36.4%; \( P = 0.03 \)), and likewise it was lower in the standard 3-dose regimen of rFVIIa compared with the aPCC group, although statistical significance was not reached (9.1% versus 36.4%; \( P = 0.07 \)).

Analysis using a unified Bayesian meta-regression model has suggested that a typical rFVIIa (90 µg/kg every 3 hours) will resolve joint bleeding more effectively than a typical aPCC regimen (75 IU/kg every 12 hours) after 12, 24 and 36 hours. A systematic review of the cost-effectiveness of rFVIIa and aPCC in the treatment of minor/moderate bleeding episodes for hemophilia patients with inhibitors has also suggested that rFVIIa may be a cost-effective alternative to treatment with aPCC. In 7 of 9 studies, rFVIIa had a lower average treatment cost.6

**Continuous infusion of rFVIIa**

Continuous rFVIIa infusion is a feasible method for the treatment of both nonsurgical37 and surgical bleeding18-41 because of its 100% stability and safety, documented by sterility for 3 days at room temperature after being reconstituted with diluents. The clearance of continuous rFVIIa infusion, calculated by clearance (mL/kg/h) = infusion rate (IU/kg/h)/plasma level (U/mL), increases in children compared to adults and remains the same level over the time of treatment.43 The amount of 1200 µg rFVIIa is equivalent to 60,000 IU. The median clearance in adults was 56 mL/kg/h and 86 mL/kg/h in children. Therefore, continuous rFVIIa infusion to maintain a required level depends on an individual’s clearance of rFVIIa. Normally, the estimated infusion rate of 16.5 µg/kg/h can raise the plasma level closed to 10 U/mL. This level is widely considered as an acceptable minimal value to maintain hemostasis.30,43,45 The advantages of continuous infusion included the 50% reduction of rFVIIa requirements when compared with the bolus injection and the stability of activity during infusion.39

Most of the protocols of continuous rFVIIa infusion start with a rFVIIa bolus at a dose of 90 µg/kg initially and every 2 hours during surgery, followed by continuous infusion to maintain a plasma level above 10 U/mL. However, during the first 2 to 3 days after surgery, the level of rFVIIa was suggested to be maintained at a higher value of 24 to 56 U/mL. Then, the level was gradually decreased until the suture was stitched off. The range of total treatment duration in elective surgery was reported at 1 to 34 days.38,41,43,44,46,47

The effectiveness of this treatment in a prospective cohort study, mainly of spontaneous bleeding cases, was around 80%. However, the difference in response was the bleeding at the mucosal surface, found to be effective in only 1 of 7 patients.48 The difference in response was hypothesized to be due to the high fibrinolytic activity in the oral cavity, which can be counterbalanced by the activation of thrombin activatable fibrinolysis inhibitor (TAFI) stimulated by bolus injection. In patients with elective surgery, the effectiveness in controlling bleeding symptoms was around 33% to 85% depending on individual studies. Nonetheless, bleeding complications could be effectively controlled by additional bolus rFVIIa injection with the dose range of 60 to 90 µg/kg. The difference in response was due to the types and aggressiveness of surgery, complications after surgery such as infection, the adjuvant of other hemostatic agents such as tranexamic acid and the dose of rFVIIa used during treatment (Table 1).37-44,46,48-50

To prevent unexpected bleeding, the sequential treatment with bolus and continuous infusion was successfully reported in a patient with hip arthroplasty. A bolus injection of 150 µg/kg was given at the start of surgery followed by 120 µg/kg every 2.5 hours for the first 2 days and 90 µg/kg every 3 hours for the third day. Then, continuous infusion was subsequently administered for the rest of the treatment course.49

Similar to other factor concentrates, the prevention of thrombophlebitis is required. Standard heparin and low-molecular-weight heparin (LMWH) were studied by adding to the rFVIIa solution. The result showed that the rFVIIa activity in the standard heparin mixture was decreased by 50% within 4 days. Therefore, parallel infusions of standard heparin or normal saline or adding LMWH to the mixture can be used to prevent thrombophlebitis.40

**Hemostasis for major surgery**

Major surgery includes exploratory laparotomy, surgery in the vital organs such as brain, heart and lungs, and orthopedic procedures of bone fixation for fractures, hip and knee arthroplasty, arthrodeses, open synovectomy, osteotomy, pseudotumor removal and hardware such as plates and intramedullary...
### Table 1: Type of bleeding or surgery, dose and response of treatment in previous reports of rFVIIa infusion

<table>
<thead>
<tr>
<th>Year</th>
<th>Author</th>
<th>Bleeding/surgery</th>
<th>Age (yr)</th>
<th>Inhibitor (BU)</th>
<th>Target FVII:C (U/mL)</th>
<th>Dose of rFVIIa</th>
<th>Duration (h)</th>
<th>Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Initial</td>
<td>Continuous</td>
<td>Total dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(µg/kg)</td>
<td>(µg/kg/h)</td>
<td>(mg/kg)</td>
</tr>
<tr>
<td>1996</td>
<td>Schulman et al</td>
<td>Total knee arthroplasty</td>
<td>32</td>
<td>500</td>
<td>10</td>
<td>90</td>
<td>15.5</td>
<td>340b</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 manipulations of the right knee contracture</td>
<td>12</td>
<td>800</td>
<td>10</td>
<td>90</td>
<td>31</td>
<td>50, 61.2</td>
</tr>
<tr>
<td>1998</td>
<td>Montoro et al</td>
<td>Insertion of central venous line</td>
<td>6</td>
<td>18</td>
<td>10–20</td>
<td>90</td>
<td>7.6</td>
<td>1</td>
</tr>
<tr>
<td>1999</td>
<td>Lorenzo et al</td>
<td>Evacuation of clot from knee joint</td>
<td>15</td>
<td>&gt;50</td>
<td>6.3–10.4</td>
<td>90</td>
<td>20</td>
<td>nd</td>
</tr>
<tr>
<td>2000</td>
<td>Baudo et al</td>
<td>Revision of electrocatheter</td>
<td>52</td>
<td>17</td>
<td>5.2–6.9</td>
<td>90</td>
<td>11.5</td>
<td>5.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Massive hemoperitoneum</td>
<td>26</td>
<td>12</td>
<td>11–14</td>
<td>90</td>
<td>20</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hematoma at buttoc</td>
<td>76</td>
<td>620</td>
<td>15–24</td>
<td>90</td>
<td>15.4</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hematoma at thorax</td>
<td>57</td>
<td>18</td>
<td>10–14</td>
<td>90</td>
<td>10–18</td>
<td>2.1</td>
</tr>
<tr>
<td>2000</td>
<td>Chuansumrit et al</td>
<td>Bleeding at hard palate</td>
<td>2</td>
<td>220</td>
<td>10</td>
<td>90</td>
<td>16.5</td>
<td>4.45</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bleeding at tongue</td>
<td>2</td>
<td>900</td>
<td>10</td>
<td>90</td>
<td>16.5</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Iliopsoas hematoma</td>
<td>19</td>
<td>330</td>
<td>10</td>
<td>90</td>
<td>16.5</td>
<td>0.97</td>
</tr>
<tr>
<td>2000</td>
<td>Tagariello et al</td>
<td>Total hip replacement</td>
<td>32</td>
<td>14</td>
<td>8–24</td>
<td>120</td>
<td>30</td>
<td>9.93</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total hip replacement</td>
<td>29</td>
<td>700</td>
<td>13–56</td>
<td>120</td>
<td>42</td>
<td>9.32</td>
</tr>
<tr>
<td>2001</td>
<td>Smith et al</td>
<td>8 elective surgery</td>
<td>33–76</td>
<td>&lt;0.5–330</td>
<td>4–13</td>
<td>90</td>
<td>16.5</td>
<td>nd</td>
</tr>
<tr>
<td>2002</td>
<td>Mauser-Bunschoten et al</td>
<td>43 bleeding episodes</td>
<td>adult</td>
<td>nd</td>
<td>10</td>
<td>90</td>
<td>17–18</td>
<td>nd</td>
</tr>
<tr>
<td>2002</td>
<td>Perez et al</td>
<td>Hip arthropathy</td>
<td>40</td>
<td>8</td>
<td>7–39</td>
<td>150</td>
<td>7–15</td>
<td>6.3</td>
</tr>
<tr>
<td>2003</td>
<td>Tagariello et al</td>
<td>Hip and knee replacement</td>
<td>44</td>
<td>nd</td>
<td>18–42</td>
<td>104</td>
<td>40</td>
<td>8.57</td>
</tr>
</tbody>
</table>

**Notes:** a. Total dose (mg); b. Tear cephalic vein; c. D1–2: 120 µg/kg every 2.5 hours, D3: 90 µg/kg every 3 hours; d. D1–3: 40 µg/kg/h, D4–5: 33 µg/kg/h, D6–9: 30 µg/kg/h, D10–13: 21 µg/kg/h.

**Abbreviations:** nd, no data; E, effective response; additional bolus injection not required; IE, ineffective response; additional bolus injection required.
nail removal. The earliest major surgical procedure of an open knee joint synovectomy in a hemophilia patient with inhibitors using rFVIIa was first reported by Hedner et al in 1988. Ingerslev et al have shown the effectiveness of 12 hemophilia patients with inhibitors undergoing surgery by giving a mean dose of rFVIIa 99 µg/kg every 2 to 3 hours for up to 2 days after which dosage intervals were prolonged. The results revealed excellent responses in 11 cases and an effective response in one case.

A prospective, double-blind, randomized trial that compared 2 doses of rFVIIa (35 and 90 µg/kg) in hemophilia patients with inhibitors who were undergoing 18 minor and 11 major surgeries was reported in 1998. Bolus injections of rFVIIa were given every 2 hours for the first 48 hours. Thereafter, the same dose was given every 2 to 6 hours for an additional 3 days. A significant difference in efficacy in terms of maintaining postoperative hemostasis favoring the high-dose group was observed from day 3 onward, although both doses were similarly effective intraoperatively.

Moreover, an international series of 108 cases of elective surgeries performed in nine hemophilia centers worldwide was published in 2004. However, only 17 major orthopedic surgeries under the cover of rFVIIa were included in the series. The outcome revealed 14 good results, 1 fair result and 2 poor outcomes. Furthermore, a case report and case series of major surgeries among hemophilia patients with inhibitors using rFVIIa ranging from 90 to 300 µg/kg every 2 hours in the first 24 hours followed by 90 to 120 µg/kg with prolonged intervals of 3 to 6 hours have gradually been reported, with effective response rates ranging from 66% to 100%.

In 2009, a consensus protocol for the use of rFVIIa in elective orthopedic major surgeries in hemophilia patients with inhibitors was published. It was based on a review of published data and the personal experience of a group of expert physicians in Europe. According to the recommendations, major surgeries should be performed at a comprehensive hemophilia center with the availability of expert physicians in the morning, early in the week. Other protocols were given as follows. It is essential for the expert physicians to closely monitor the patient for a few days after the surgery. An initial bolus dose of rFVIIa in the range of 120 to 180 µg/kg is given at the start of surgery followed by 90 µg/kg at 2-hour intervals throughout surgery. A final intraoperative bolus should be given just prior to final reduction in the case of hip arthroplasty or release of the tourniquet in the case of knee arthroplasty. After 48 hours of 2-hour boluses, the dosing intervals may be increased to 3 hours for the following 48 hours and to 4 hours for the next 72 hours. At day +8 after the surgery, the intervals between doses may be lengthened to 6 hours. The topical application of a fibrin sealant during the intraoperative period is helpful in minimizing capillary oozing. Additionally, the concomitant administration of an antifibrinolytic agent such as tranexamic acid is recommended, unless there is a strong contraindication. It may enhance the effect of rFVIIa and improve hemostasis.

In cases of bleeding complications after the surgery, the next scheduled dose of rFVIIa should be brought forward and a dose increase should be considered or an additional 5 doses of 90 µg/kg of rFVIIa should be given every 2 hours until the hemostasis is achieved. If the measures are not been successful, changing treatment to aPCC should be considered. Importantly, the postoperative physiotherapy should be covered by a bolus of rFVIIa. These protocols have been used in 10 major orthopedic surgeries involving 13 procedures in 5 comprehensive care centers. The intraoperative hemostasis was satisfactorily achieved; however, 2 cases were reported of postoperative bleeding. The first case had bleeding in the knee 5 days after arthroplasty. The patient did not receive tranexamic acid perioperatively and the bleeding resolved after the dose of rFVIIa was increased. The second case exhibited bleeding 8 hours after shoulder arthroplasty. The patient had received tranexamic acid and the bleeding gradually resolved 5 days after switching the treatment to aPCC. The cost of medication to cover this type of surgery was approximately US$750,000 which is 10 times greater than that for a person without inhibitors. Although solving the problem in the target joint initially is costly, it will decrease the tendency for further frequent bleeding in that target joint and also decrease the frequency of bleeding in other joints such as the shoulders or elbows if the patient has to use crutches for the next 5 to 9 years.

**Sequential/concomitant therapy of rFVIIa and aPCC**

An initial strikingly excellent response of hemophilia patients with inhibitors to rFVIIa after aPCC treatment was observed by Key et al. The possible synergy between rFVIIa and aPCC in vivo and in vitro was demonstrated in 3 patients. It might be due to the presence of activated clotting factors in the aPCC prior to rFVIIa administration. Sequential therapy of rFVIIa and aPCC was reported among ten children who had failed their home treatment with rFVIIa and aPCC alone (n = 9). They received alternating doses of rFVIIa (80 to 225 µg/kg/dose) and aPCC (35 to 80 IU/kg/dose) every
6 hours; and 1 to 3 doses of rFVIIa were given every 2 hours between aPCC doses. Hemostasis was achieved and no thromboembolic (TE) event was detected. However, such patients should be hospitalized and under the supervision of experts in hematology to guard against the risk of TE complication. Antifibrinolytic agents should be avoided.

Recently, Martinowitz et al reported the use of concomitant infusions of low doses of rFVIIa (30 to 70 µg/kg/dose) and aPCC (20 to 30 IU/kg/dose) in 5 adult hemophilia A patients with inhibitors (8 to 1300 BU), aged 17 to 60 years who were refractory to rFVIIa administration. They exhibited a total number of 400 bleeding episodes, mainly hemarthrosis with excellent hemostasis; they required 1 dose of concomitant therapy if initiated early after onset of bleeding for 1 to 2 hours, and 2 to 3 doses daily every 6 hours for some target joints and large hematoma. The concomitant therapy every 6 hours for 24 hours followed by 3 times daily and thereafter 2 times daily for a total of 72 hours has been successfully used for papilotomy and gallbladder stent insertion. No adverse events and no disseminated intravascular coagulation were observed following these infusions.

Prophylaxis with rFVIIa

Prophylaxis in hemophilia patients with inhibitors is not generally recommended due to the concern of efficacy, TE complications, and cost. The first report described the use of a daily dose of 240 µg/kg in a hemophilia B patient with high titers during the perioperation and postoperative intensive physical rehabilitation for the correction of a knee contracture. To date, rFVIIa prophylaxis has been reported in 45 hemophilia patients with inhibitors as shown in Table 2. Of note, 22 patients were included in a randomized, double-blind study of receiving daily prophylaxis of rFVIIa 90 µg/kg or 270 µg/kg for 3 months. The frequencies of bleeding episodes were significantly reduced by 45% and 59% during the prophylaxis with 90 and 270 µg/kg, respectively (P < 0.0001) compared to on-demand therapy. However, no significant difference was detected between the doses. Interestingly, the reduction of bleeding episodes was maintained during the postprophylaxis period. The effectiveness of giving pharmacological doses of rFVIIa used in the prophylaxis can be explained by the hypothesis that the extravascular diffusion of rFVIIa will be available at the site of injury. It could contribute to the hemostatic plug by increasing thrombin generation on activated platelets.

Since the frequency of bleeding episodes during prophylaxis was significantly reduced, the days of hospitalization, absences from work and school, and equipment to increase mobility were significantly reduced, which led to marked improvement of health and related quality of life compared with on-demand therapy. No TE complication was reported. However, the cost derived from prophylaxis is more expensive than the prior therapy with factor VIII concentrate but cheaper than the prior immune tolerance therapy.

Prophylaxis with rFVIIa is a potential option for preventing episodes of joint bleeding and protecting joint damage while awaiting a decline in inhibitor titers before immune tolerance therapy can be initiated. Moreover, an international survey of attitudes towards secondary prophylaxis with rFVIIa in hemophilia A patients with inhibitors was conducted by interviewing 31 physicians from hemophilia centers and 20 health care providers in Europe and the US. The results revealed a positive attitude and more support for secondary prophylaxis in children than in adults.

Thromboembolic complications

Reports on TE complications related to the use of rFVIIa in hemophilia patients with inhibitors are rarely found. From 1996 to 2003 over 700,000 doses (90 µg/kg) were given, there have been 25 TE events found in hemophilia patients with inhibitors and acquired hemophilia patients. An additional 800,000 doses of rFVIIa have been administered from 2003 to 2006 during which time a total of 30 TE events and 6 TE event-associated fatal events occurred among hemophilia patients with inhibitors and acquired-hemophilia patients. Two additional studies reviewed the MedWatch pharmacovigilance program of US Food and Drug administration for TE adverse events occurring in patients administered rFVIIa in the period from April 1999 through June 2002 and from March 25, 1999 through December 31, 2004. The first study reported 67 TE adverse events in rFVIIa recipients compared to 16 events in aPCC (FEIBA®) recipients in hemophilia patients with inhibitors and acquired hemophilia patients. The incidence rate ratio of 2.98 (CI 1.71–5.52) suggested the higher TE occurrence in rFVIIa than aPCC recipients. The second study reported 185 TE events described in 168 reports. One hundred and nine reports described TE events occurring mainly in unlabeled uses for bleeding in nonhemophilia patients (n = 92) and occurring less often in hemophilia patients (n = 17). Additional 59 reports described TE events occurred in nonhemophilia patients enrolled in postlicensure trials of unlabeled uses. The TE events involved cardiovascular accidents (n = 39), acute myocardial infarction (n = 34), other arterial thromboses (n = 26), pulmonary embolism (n = 32), other venous thromboses including deep vein thrombosis (n = 42), and clotted devices (n = 10).
Table 2 Patient characteristics, regimen, duration and number of bleeding at pre-prophylaxis and prophylaxis period

<table>
<thead>
<tr>
<th>Year</th>
<th>Author</th>
<th>Hemophilia A/B (case)</th>
<th>Inhibitor (BU)</th>
<th>Age (yr)</th>
<th>Dose of rFVIIa</th>
<th>Duration</th>
<th>Number of bleeds</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pre-prophylaxis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2/80 daysb</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>21 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>32/14 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7/12 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.2/month</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.8/month</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.6/month</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.0/month</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.3/month</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.2/month</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.5/month</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.25–8.33/month</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0–2.25/month</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4/3 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1/9 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1/15 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1/15 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3/3 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1/19 months</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: aWheelchair-bound with bilateral knee contracture of 30 degrees; bTraction and casting/wedging procedures were successfully achieved with only 2 trauma-related bleeding episodes.

Seventy-three (52%) of 144 patients with time information in the first 24 hours after the last rFVIIa infusion for which 30 events occurred within 2 hours. Limited data were available for concomitant risk factors and the underlying medical conditions of the patients, which complicates the analysis. Nevertheless, the average risk of a TE event was approximately 3.75 per 100,000 infusions. The majority of events were found in off-label use and with concomitant hemostatic agents such as the sequential use of rFVIIa and aPCC. Ultimately, the incidence of TE events with the use of rFVIIa in hemophilia patients with inhibitors was extremely low, much less than 1%, and appeared unrelated to dose. No TE event was ever found in any hemophilia patient receiving a single high dose of 270 μg/kg of rFVIIa.

For continuous infusion, the dose is lower than that of bolus injection; therefore, the activation of the hemostatic system would be less than that of the bolus injection. The activation of hemostasis was demonstrated in 4 patients receiving continuous infusion over 4 to 18 days. The prothrombin fragments (F1 + 2) and D-dimer were increased after bolus injection and unchanged throughout the treatment period of continuous infusion without clinical thromboembolism.

Discussion

The development of inhibitors to factor VIII and factor IX is one of the most challenging complications found among hemophilia patients. Less than optimal treatment and lack of prophylaxis lead to chronic arthropathy, deformity and early death. Elective and orthopedic corrective surgeries are often delayed or canceled due to the difficulty in achieving hemostasis. Prior to 1988, the only available factor concentrate was aPCC. Although aPCC is effective in controlling bleeding episodes and achieving hemostasis for surgeries, the reported number of major surgeries is relatively minimal. The discovery of plasma derived factor VIIa and rFVIIa has opened a new era for hemophilia patients with inhibitors to have treatment similar to those without inhibitors.

The initial constraints of rFVIIa are its short half-life and dose-finding. From compassionate-use programs...
and independent studies, rFVIIa at the dose of 90 µg/kg appears to be the standard dose commonly used among patients. A 2-hour interval is applied for the first 24 to 48 hours and thereafter increases to 3 to 6 hours according to the severity of bleeding manifestation, efficacy of bleeding control, and relief of pain. This regimen can also be applied for minor and major surgeries; however, a higher initial dose of 120 to 180 µg/kg is required for the major surgery. In cases of unexpected bleeding, increasing the dose of rFVIIa is suggested. Since some patients may have a shorter half-life of rFVIIa (normal children 1.32 hours and normal adult 2.72 hours) and a higher clearance rate (normal children 67.0 mL/kg/h and normal adult 32.8 mL/kg/h), they will require a higher dose (200–300 µg/kg) of rFVIIa to achieve the proper clinical response. A neurosurgical resection of a malignant glioneuronal tumor was reported by giving a bolus of 270 µg/kg every 2 hours during the first 24 hours, followed by 180 µg/kg every 3, 4, and 6 hours at days 2 to 3, 4 to 10, and 11 to 15, respectively. Therefore, it should be noted that the optimal dose of rFVIIa depends upon individual half-life and clearance rate of rFVIIa as well as the surgical procedure and bleeding sites. Moreover, elective surgery should be deferred until the inhibitor level is <5 BU, and may require the use of high doses of factor VIII or IX concentrates in cases of uncontrolled intraoperative or postoperative bleeding complications.

The earlier the treatment is given, the more effective will be the outcome. The most effective early treatment is for home treatment programs. The dose of rFVIIa of 90 µg/kg, 3 times, 3 hours apart is as effective as a single dose of 270 µg/kg. The single dose is convenient especially among pediatric age groups who are needle phobic and have poor venous access. One study has demonstrated the efficacy of effective bleeding control of rFVIIa at the dose of >200 µg/kg for mild to moderate bleeding at the muscle and joint compared with <200 µg/kg. In cases of prophylaxis, the dose of rFVIIa ranging from 200 to 250 µg/kg/week to 90 to 270 µg/kg daily or every 6 to 12 hours has been reported. It is an option for preventing joint bleeding and protecting joint damage before the initiation of immune tolerance therapy. Recombinant factor VIIa is selected due to the awareness of the anamnestic response provoked by residual factor VIII antigen contained in aPCC. However, the number of patients receiving prophylaxis is rather small. Further studies on the most appropriate dose and with a larger number of enrolled subjects are warranted. Interestingly, the incidence of TE events among hemophilia patients with inhibitors receiving on-label rFVIIa is extremely low, much less than 1%. The analysis of such TE events from rFVIIa was complicated by the limited data on concomitant and underlying disease risk factors. However, the sequential and concomitant therapy of rFVIIa and aPCC should be given with caution. Further, clinical manifestations and laboratory investigations should be closely monitored by hematology experts in the comprehensive hemophilia center setting.

The only constraint is the cost of rFVIIa to cover bleeding episodes, surgery and prophylaxis for patients with inhibitors, which much higher than for patients without inhibitors. However, it has a very low risk, and is convenient and cost-effective in the long term. It will improve the physical function and functional status of patients. The cost of treating subsequent bleeding episodes at the target joints and other related joints, deformity and disability in the following years should be included in the budget calculation. A hypothetical model of a hemophilia patient after receiving joint replacement with an expected reduction in frequency of bleeding of 80% from the assumed 12 bleeding episodes per year for 5 years showed that the cost of utilizing rFVIIa was cost-effective. Moreover, the health related quality of life, psychosocial aspects and self-esteem of the patients as well as their family members should be included in the cost-effectiveness evaluation.

**Conclusion**

Recombinant factor VIIa has opened a new era of effective treatment for hemophilia patients with inhibitors worldwide. Hemostasis for bleeding episodes, surgery and prophylaxis has been successfully accomplished. The only constraint is the extremely high cost of medication. However, it is cost-effective if the subsequent bleeding episodes at the target joints and other related joints, deformity, disability, and poor health-related quality of life over the next several years are considered in the evaluation.

**Acknowledgment**

The study was supported by the Thailand Research Fund-Senior Research Scholar 2006 (A.C.).

**Disclosures**

Ampaiwan Chuansumrit and Pantep Anghaisuksiri have received honoraria for speaking at conferences supported by Novo Nordisk and Baxter. Nongmunch Sirachainan stated that she had no interest which might be perceived as posing a conflict or bias.
References


